Antimicrobial and Antibiofilm Effects of Peptides from Venom of Social Wasp and Scorpion on Multidrug-Resistant
Overview
Authors
Affiliations
Intravascular stent infection is a rare complication with a high morbidity and high mortality; bacteria from the hospital environment form biofilms and are often multidrug-resistant (MDR). Antimicrobial peptides (AMPs) have been considered as alternatives to bacterial infection treatment. We analyzed the formation of the bacterial biofilm on the vascular stents and also tested the inhibition of this biofilm by AMPs to be used as treatment or coating. Antimicrobial activity and antibiofilm were tested with wasp (Agelaia-MPI, Polybia-MPII, Polydim-I) and scorpion (Con10 and NDBP5.8) AMPs against clinical strains. formed a biofilm on the vascular stent. Agelaia-MPI and Polybia-MPII inhibited biofilm formation with bacterial cell wall degradation. Coating biofilms with polyethylene glycol (PEG 400) and Agelaia-MPI reduced 90% of adhesion on stents. The wasp AMPs Agelaia-MPI and Polybia-MPII had better action against MDR adherence and biofilm formation on vascular stents, preventing its formation and treating mature biofilm when compared to the other tested peptides.
Wasp Venom: Future Breakthrough in Production of Antimicrobial Peptides.
Bhattacharya B, Bhattacharya S, Khatun S, Bhaktham N, Maneesha M, Subathra Devi C Protein J. 2024; 44(1):35-47.
PMID: 39633224 DOI: 10.1007/s10930-024-10242-9.
Novel Synthetic Peptide Agelaia-12 Has Improved Activity Against Complex.
Coelho A, Barbosa L, da Costa A, Kipnis A, Junqueira-Kipnis A Pathogens. 2024; 13(11).
PMID: 39599547 PMC: 11597844. DOI: 10.3390/pathogens13110994.
Borges K, Costa V, Neves Junior B, Kipnis A, Junqueira-Kipnis A PLoS One. 2024; 19(9):e0307913.
PMID: 39325805 PMC: 11426455. DOI: 10.1371/journal.pone.0307913.
Ji F, Tian G, Shang D, Jiang F Front Microbiol. 2023; 14:1258469.
PMID: 37942076 PMC: 10628664. DOI: 10.3389/fmicb.2023.1258469.
Bertelsen M, Lacey M, Nichol T, Miller K Pharmaceutics. 2023; 15(10).
PMID: 37896158 PMC: 10610086. DOI: 10.3390/pharmaceutics15102399.